60 Degrees Pharmaceuticals (NASDAQ:SXTP) Stock Rating Lowered by Wall Street Zen

60 Degrees Pharmaceuticals (NASDAQ:SXTP) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday.

SXTP has been the subject of several other reports. Ascendiant Capital Markets reduced their target price on 60 Degrees Pharmaceuticals from $11.20 to $4.20 and set a “buy” rating for the company in a report on Thursday. HC Wainwright boosted their target price on 60 Degrees Pharmaceuticals from $6.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $14.10.

60 Degrees Pharmaceuticals Stock Up 1.1%

SXTP stock opened at $1.76 on Friday. 60 Degrees Pharmaceuticals has a 52-week low of $1.29 and a 52-week high of $17.68. The stock has a market cap of $4.65 million, a price-to-earnings ratio of -0.13 and a beta of 3.27. The business has a fifty day moving average of $2.62 and a two-hundred day moving average of $3.69.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.